Target intelligence / Profile preview

Thioredoxin, mitochondrial (TXN2)

Target
TXN2
Molecular classification
Enzyme, Redox protein, Disulfide reductase, Thioredoxin family
01

Overview

Thioredoxin, mitochondrial (TXN2), also known as thioredoxin-2, is a small (~12 kDa) redox-active protein found in the mitochondrial matrix, encoded by the human TXN2 gene on chromosome 22[1][4][6]. It is a member of the conserved thioredoxin family, characterized by a Trp-Cys-Gly-Pro-Cys active site motif, and functions as a disulfide reductase, maintaining proteins in a reduced state[1][3][6]. TXN2 regulates mitochondrial redox homeostasis, protects against oxidative stress by scavenging reactive oxygen species, and inhibits oxidant-induced apoptosis, supporting mitochondrial membrane potential and cell survival[1][3][4]. Dysregulation of TXN2 is implicated in cancer, neurodegeneration, cardiovascular diseases, and other conditions associated with oxidative stress, making it a relevant therapeutic target for diseases involving mitochondrial dysfunction and redox imbalance[1][4][6].

Other names
thioredoxin-2Trx2mitochondrial thioredoxinTRX-2
02

Mechanism of action

Inhibition of thioredoxin 2 reduces mitochondrial antioxidant capacity, increases ROS, and promotes apoptosis in cancer or stressed cells[1]. Modulation of the thioredoxin system may sensitize cells to oxidative stress and chemotherapies.

03

Biological functions

Redox homeostasisProtection against oxidative stressRegulation of mitochondrial membrane potentialApoptosis regulationReactive oxygen species (ROS) scavenging
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInflammationOther oxidative stress-related disorders
05

Safety considerations

Potential off-target toxicity, since thioredoxin 2 is ubiquitously expressed and essential for normal cellular redox regulation.Inhibition could cause mitochondrial dysfunction and cell death in normal tissues.
06

Interacting drugs

No specific drugs directly targeting thioredoxin 2 are FDA-approved (as of 2024), but experimental compounds (e.g. auranofin) inhibit the thioredoxin system[1]. Some anti-cancer therapies are being developed to target thioredoxin pathways.
07

Biomarkers

Thioredoxin 2 expression levels may serve as a biomarker for mitochondrial redox status, cellular stress, and susceptibility to oxidative injury in diseases such as cancer[1].

Beyond the preview

Go deeper on Thioredoxin, mitochondrial (TXN2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thioredoxin, mitochondrial (TXN2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call